Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efpeglenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms AMPLITUDE-O
  • Sponsors Sanofi

Most Recent Events

  • 20 Feb 2023 Results exploring relationship between Efpeglenatide dose and cardiovascular outcomes during follow-up of 1.8 years published in the Circulation
  • 10 Apr 2022 This trial has been completed in Spain (Date of the global end of the trial : 10-Dec-2020), according to European Clinical Trials Database record.
  • 15 Nov 2021 Results assessing impact of SGLT2i on the efficacy (primary and secondary endpoints, including heart failure and renal events) and safety of efpeglenatide, presented at the American Heart Association Scientific Sessions 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top